Mizuho analyst Anthony Petrone lowered the firm’s price target on Nevro to $16 from $20 and keeps a Neutral rating on the shares ahead of the Q1 report. The analyst cites “tepid feedback on an expeditious recovery “0of the core back and leg market into 2024, from channel check calls with pain physicians, for the target drop.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVRO: